PharmaMar begins a Phase I study of PM1183 in Japan for the treatment of solid tumors

PharmaMar (MSE:PHM) has announced the start of an open-label, multicenter, Phase I study in Japan to evaluate the recommended dose (RD) of PM1183 (lurbinectedin) in patients with certain types of unresectable/advanced solid tumors. The main objective of the study is to determine the recommended dose of PM1183 in Japanese patients. Furthermore, the secondary objective will…

Details

PharmaMar begins a Phase I study of PM1183 in Japan for the treatment of solid tumors

PharmaMar (MSE:PHM) has announced the start of an open-label, multicenter, Phase I study in Japan to evaluate the recommended dose (RD) of PM1183 (lurbinectedin) in patients with certain types of unresectable/advanced solid tumors. The main objective of the study is to determine the recommended dose of PM1183 in Japanese patients. Furthermore, the secondary objective will…

Details